

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant ID1601

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bellicum (rivogenlecleucel) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • African Caribbean Leukaemia Trust • Anthony Nolan • Black Health Agency • Bloodwise • Cancer Black Care • Cancer Equality • Cancer 52 • Childhood Cancer Parents Alliance • Children with Cancer • Chronic Lymphocytic Leukaemia Support Association • Chronic Myeloid Leukaemia Support Group • CLIC Sargent • Contact a Family • DKMS • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patient Voice • Leukaemia Cancer Society • Leukaemia Care • Lymphoma Action • Macmillan Cancer Support • Maggie's Centre • Marie Curie • MDS UK Patient Support Group • Muslim Council of Britain • Myeloma UK • Primary Immunodeficiency UK • Sickle Cell Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematological Malignancies Group • Genomics England • Institute of Cancer Research • Leuka • Leukaemia Busters • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Oxford Biomedical Research Centre • MRC Clinical Trials Unit

Provisional stakeholder list for the technology appraisal of rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant ID1601
Issue date: March 2019

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • South Asian Health Foundation • Specialised Healthcare Alliance • Teenage Cancer Trust • Tenovus Cancer Care • The Aplastic Anaemia Trust • UK Primary Immunodeficiency Network <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Blood Transfusion Society • British Committee for Standards in Haematology • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Genetic Medicine • British Society of Blood and Marrow Transplantation • British Society for Haematology • British Society of Immunology • British Transplantation Society • Cancer Research UK • Children’s Cancer and Leukemia Group • ESPRIT • NHS Blood and Transplant • Royal College of Anesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiology • UK Forum on Haemoglobin Disorders • UK Health Forum • UK Oncology Nursing Society • UK Clinical Pharmacy Association 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Chronic Lymphocytic Leukaemia Forum • UK Primary Immunodeficiency Network <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Leeds North CCG • NHS Vale Royal CCG • Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.